Incyte hits endpoint in 2nd pivotal atopic dermatitis trial

Incyte hits endpoint in 2nd pivotal atopic dermatitis trial

Source: 
Fierce Biotech
snippet: 

A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has met its primary endpoint. The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.